- Home
- IAUX vs ETON Comparison
IAUX vs ETON Comparison
Compare IAUX & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAUX | ETON |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IAUX | ETON |
|---|---|---|
| Price | $1.52 | $50.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.50 | ★ $71.50 |
| AVG Volume (30 Days) | ★ 7.9M | 523.9K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $95,193,000.00 | $79,950,000.00 |
| Revenue This Year | $108.00 | $87.26 |
| Revenue Next Year | $81.33 | $47.21 |
| P/E Ratio | ★ N/A | $125.17 |
| Revenue Growth | 89.12 | ★ 104.94 |
| 52 Week Low | $0.89 | $14.27 |
| 52 Week High | $2.24 | $66.37 |
Technical Indicators
Market Signals| Indicator | IAUX | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 37.05 |
| Support Level | $1.41 | $48.79 |
| Resistance Level | $1.54 | $60.60 |
| Average True Range (ATR) | 0.07 | 3.33 |
| MACD | -0.01 | -0.58 |
| Stochastic Oscillator | 28.30 | 13.48 |
Price Performance
Historical ComparisonAbout IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.